Axon is a Series A company developing a novel neuromodulation approach to treat heart failure with funding from APVC, Deerfield, and a leading strategic partner.

EP Sciences is an early stage company developing a novel method to reduce the severe pain associated with implantable defibrillator shocks. EP Science has received an SBIR Phase IIb grant along with funding from Broadview Ventures.

Launched with $10 million in Series A financing from top-tier venture investors Third Rock Ventures and SV Life Sciences, Cibiem is leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company is testing its unique CBM physiological approach in first-in-man clinical trials.

CorVent Medical is developing the RESPOND-19™ Ventilator, a reliable and intuitive critical care respiratory support with rapid and affordable deployment during times of greatest need. It is optimized for use during the COVID-19 pandemic

A key partner in Coridea’s product development for Military applications, VVV6 is a Wyoming-based, veteran-owned, biotechnology company that identifies gaps in military medicine and closes them using solution-driven products.

Coridea identified renal nerve traffic to and from the kidney as a target for a new, previously unexplored device development to treat hypertension. They licensed the renal denervation technology — now marketed as Symplicity® — to The Foundry, and Ardian, Inc. was formed. Medtronic Inc. acquired Ardian in November 2010 for $800 million, the highest ever paid for a venture capital-backed medical device company in the pre-commercialization stage. The Symplicity® Catheter System™ by Medtronic Ardian was named the 2011 Edison Awards winner and received many other innovation awards.

Founded in 2006, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē ® System is an innovative implantable neurostimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea. Sorin Group invested in on-going clinical testing of the remedē System in the U.S. Commercial launch of the product by Sorin in selected European countries started in 2015.

Coridea invented a new therapy, Aquapheresis, which allows for the safe and expedient removal of large volumes of fluid. Patients receiving Aquapheresis showed a remarkable 50 percent reduction in the number of re-hospitalizations for heart failure over the standard of care in trials. CHF Solutions Inc. obtained FDA approval of the Aquadex™ System, which is now considered standard of care for drug resistant fluid overload. Gambro AB acquired CHF Solutions in 2010.

Coridea recognized an unmet clinical need in the area of Contrast-Induced Nephropathy (CIN) — a form of acute renal failure caused by exposure to contrast media during image-guided cardiology and radiology procedures. Coridea discovered that a balanced high volume infusion of IV fluid flushes the patient’s kidneys and reduces damage from radiocontrast. The device based on Coridea’s discovery was named RenalGuard. The company recently spun out Reprieve Cardiovascular, which is exploring the use of this technology to treat patients with Acute Heart Failure.

Coridea recognized an unmet clinical need in the area of Contrast-Induced Nephropathy (CIN) — a form of acute renal failure caused by exposure to contrast media during image-guided cardiology and radiology procedures. Coridea discovered that a balanced high volume infusion of IV fluid flushes the patient’s kidneys and reduces damage from radiocontrast. The device based on Coridea’s discovery was named RenalGuard. The company recently spun out Reprieve Cardiovascular, which is exploring the use of this technology to treat patients with Acute Failure.